Salvage Chemotherapy After Nivolumab for Recurrent or Metastatic Head and Neck Carcinoma

被引：22
|
作者：
Fushimi, Chihiro [1 ]
Okamoto, Isaku [2 ]
Matsuki, Takashi [3 ]
Masubuchi, Tatsuo [1 ]
Okada, Takuro [2 ]
Sato, Hiroki [2 ]
Tsukahara, Kiyoaki [2 ]
Kondo, Takahito [4 ]
Yamashita, Taku [3 ]
Hanyu, Kenji [1 ,2 ]
Omura, Go [5 ]
Takahashi, Hideaki [6 ]
Tada, Yuichiro [1 ]
Miura, Kouki [1 ]
机构：
[1] Int Univ Hlth & Welf Mita Hosp, Dept Head & Neck Oncol & Surg, Tokyo, Japan
[2] Tokyo Med Univ, Dept Otorhinolaryngol Head & Neck Surg, Tokyo, Japan
[3] Kitasato Univ, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Sagamihara, Kanagawa, Japan
[4] Tokyo Med Univ, Hachioji Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, Hachioji, Tokyo, Japan
[5] Natl Canc Ctr, Dept Head & Neck Oncol, Tokyo, Japan
[6] Yokohama City Univ, Sch Med, Dept Head & Neck Surg, Yokohama, Kanagawa, Japan
来源：
ANTICANCER RESEARCH | 2020年 / 40卷 / 09期
关键词：
Salvage chemotherapy; Immune checkpoint inhibitor; nivolumab; head and neck carcinoma; recurrent or metastatic; best supportive care; SQUAMOUS-CELL CARCINOMA; OPEN-LABEL; PHASE-II; CETUXIMAB; DOCETAXEL; CANCER; PEMBROLIZUMAB; PACLITAXEL; EFFICACY; THERAPY;
D O I：
10.21873/anticanres.14532
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background/Aim: The treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (RIM HNSCC) has remained challenging. The effect of salvage chemotherapy (SCT) after nivolumab has been identified recently in other cancer types. The aim of this study was to examine the efficacy of SCT after nivolumab treatment in patients with RIM HNSCC. Patients and Methods: A retrospective study was conducted at four institutions in Japan. Fifty-six patients were enrolled in the study. Results: The overall survival (OS) in SCT patients was significantly longer than that in best supportive care (BSC) patients. In the SCT patients, the median OS, median progression-free survival (PFS) and objective response rate (ORR) were 7.3 months, 23 months and 36%, respectively. Prognostic factor for OS and ORR was performance score (PS) and previous radiation, respectively. Conclusion: SCT after nivolumab is associated with better clinical outcomes in patients with RIM HNSCC compared to those receiving BSC.
引用
收藏
页码：5277 / 5283
页数：7
相关论文
共 50 条
  • [1] Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
    Wakasaki, Takahiro
    Yasumatsu, Ryuji
    Masuda, Muneyuki
    Takeuchi, Toranoshin
    Manako, Tomomi
    Matsuo, Mioko
    Jiromaru, Rina
    Uchi, Ryutaro
    Komune, Noritaka
    Noda, Teppei
    Nakagawa, Takashi
    CANCERS, 2020, 12 (08) : 1 - 11
  • [2] Salvage chemotherapy after progression on immunotherapy in recurrent/metastatic squamous cell head and neck carcinoma
    Llop, Sandra
    Plana, Maria
    Tous, Sara
    Ferrando-Diez, Angelica
    Brenes, Jesus
    Juarez, Marc
    Vidales, Zara
    Vilajosana, Esther
    Linares, Isabel
    Arribas, Lorena
    Duch, Maria
    Fulla, Marta
    Brunet, Aina
    Lozano, Alicia
    Cirauqui, Beatriz
    Mesia, Ricard
    Oliva, Marc
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [3] Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma
    Wakasaki, Takahiro
    Yasumatsu, Ryuji
    Uchi, Ryutaro
    Taura, Masahiko
    Matsuo, Mioko
    Komune, Noritaka
    Nakagawa, Takashi
    AURIS NASUS LARYNX, 2020, 47 (01) : 116 - 122
  • [4] Role of programmed death-ligand 1 in predicting the treatment outcome of salvage chemotherapy after nivolumab in recurrent/metastatic head and neck squamous cell carcinoma
    Ueki, Yushi
    Takahashi, Takeshi
    Ota, Hisayuki
    Shodo, Ryusuke
    Yamazaki, Keisuke
    Horii, Arata
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2020, 42 (11): : 3275 - 3281
  • [5] Impact of salvage chemotherapy after immune checkpoint inhibitor for recurrent or metastatic head and neck cancer
    Matoba, Takuma
    Minohara, Kiyoshi
    Kawakita, Daisuke
    Sawabe, Michi
    Takano, Gaku
    Oguri, Keisuke
    Murashima, Akihiro
    Iwaki, Sho
    Tsuge, Hiroshi
    Imaizumi, Sae
    Hojo, Wataru
    Kondo, Ayano
    Tsukamoto, Koji
    Iwasaki, Shinichi
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2024, 46 (08): : 1855 - 1864
  • [6] Analysis of the benefit of salvage chemotherapy after progression on nivolumab in patients with squamous cell carcinoma of the head and neck
    Reverdy, Thibaut
    Varnier, Romain
    de Talhouet, Solene
    Duplomb, Sophie
    Bruyas, Amandine
    ORAL ONCOLOGY, 2023, 145
  • [7] Nivolumab in recurrent/metastatic head and neck cancers
    Karabajakian, Andy
    Reverdy, Thibaut
    Gau, Max
    Fayette, Jerome
    FUTURE ONCOLOGY, 2018, 14 (07) : 603 - 609
  • [8] Nivolumab for recurrent or metastatic head and neck cancer
    Tanday, Sanjay
    LANCET ONCOLOGY, 2016, 17 (11): : E483 - E483
  • [9] Chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck
    Fanucchi, M
    Khuri, FR
    SEMINARS IN ONCOLOGY, 2004, 31 (06) : 809 - 815
  • [10] Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Saleh, Khalil
    Daste, Amaury
    Martin, Nicolas
    Pons-Tostivint, Elvire
    Auperin, Anne
    Herrera-Gomez, Ruth Gabriela
    Baste-Rotllan, Neus
    Bidault, Francois
    Guigay, Joel
    Le Tourneau, Christophe
    Saada-Bouzid, Esma
    Even, Caroline
    EUROPEAN JOURNAL OF CANCER, 2019, 121 : 123 - 129
12345